Form 4: Zevra Therapeutics SVP Sells 3,000 Shares Under 10b5-1 Plan

Timothy J. Sangiovanni, SVP of Finance & Corp Controller at Zevra Therapeutics, sold 3,000 shares of common stock at $7.8626 per share on February 13, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 13, 2025, Timothy J. Sangiovanni, the SVP of Finance & Corp Controller at Zevra Therapeutics, sold 3,000 shares of the company's common stock.
• The sale was executed at a price of $7.8626 per share.
• This transaction was conducted under a pre-arranged trading plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following the transaction, Sangiovanni directly owns 16,341 shares of Zevra Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative.

Comparison to Industry Standards

• Comparing this transaction to similar insider sales at comparable pharmaceutical companies would require analyzing the frequency and size of insider transactions at those companies.
• For example, if executives at companies like BioCryst Pharmaceuticals or Global Blood Therapeutics (prior to its acquisition) regularly sold shares under 10b5-1 plans, this transaction would be viewed as typical.
• However, if insider sales are rare at peer companies, this transaction might raise more questions among investors.

Stakeholder Impact

• The sale of shares by an executive could have a minor psychological impact on shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates